Influence of Different Stem Cell Mobilization Strategies on Graft Composition and Outcome of Autologous or Allogeneic Transplantation

[1]  J. Tisdale,et al.  Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor. , 2011, Experimental hematology.

[2]  A. Ho,et al.  Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. , 2011, Cytotherapy.

[3]  H. Fung,et al.  Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis. , 2011, Experimental hematology.

[4]  H. Goldschmidt,et al.  Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients , 2010, Bone Marrow Transplantation.

[5]  V. Praloran,et al.  CD34+ cells obtained from “good mobilizers” are more activated and exhibit lower ex vivo expansion efficiency than their counterparts from “poor mobilizers” , 2010, Transfusion.

[6]  G. Tricot,et al.  Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization , 2010, Bone Marrow Transplantation.

[7]  J. Dipersio,et al.  Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  R. Stuart,et al.  Cost-Effective Use of Plerixafor for Hematopoietic Stem Cells Mobilization: Development and Validation of a Decision-Making Algorithm. , 2009 .

[9]  J. Keats,et al.  Impact of IgVH Gene Mutational Status and VH Family Usage on Chromosomal Aberrations Detected by High-Resolution Array-CGH in B-CLL. , 2009 .

[10]  A. Venditti,et al.  The Amount of Spontaneous Apoptosis Is An Independent Strong Disease Progression Indicator in B-Cell Chronic Lymphocytic Leukemia (B-CLL) , 2009 .

[11]  D. Dingli,et al.  A Risk Adapted Approach Utilizing Plerixafor in Autologous Peripheral Blood Stem Cell Mobilization. , 2009 .

[12]  H. Dombret,et al.  Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program. , 2009 .

[13]  E. Jacobsen,et al.  Plerixafor (Mozobil ®)Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation. , 2009 .

[14]  Jennifer R. Brown,et al.  ZAP-70 Disrupts Dipeptidyl Peptidase 2 (DPP2)-Regulated Quiescence in Chronic Lymphocytic Leukemia (CLL). , 2009 .

[15]  D. Dingli,et al.  Predicting Poor Peripheral Blood Stem Cell Mobilization in Multiple Myeloma (MM) Using Initial Peripheral CD34 Counts: Developing Target-Based Cut-Points for Early Intervention. , 2009 .

[16]  F. Bosch,et al.  Beta-2 Microglobulin Is a Strong Prognostic Marker in Patients with Chronic Lymphocytic Leukemia Submitted to Allogeneic Stem Cell Transplantation. , 2009 .

[17]  J. Dipersio,et al.  Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor. , 2009 .

[18]  R. Fiederlein,et al.  Effects of Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) and Plerixafor On Lymphocyte Subsets in Autologous Peripheral Blood Stem Cell (PBSC) Apheresis Products. , 2009 .

[19]  E. Wang,et al.  Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. , 2009, Blood.

[20]  P. Tan,et al.  G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo. , 2009, Clinical immunology.

[21]  U. Popat,et al.  Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma , 2009, American journal of hematology.

[22]  Michael L. Wang,et al.  Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  R. Fanin,et al.  Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study , 2009, Bone Marrow Transplantation.

[24]  Yu-Hong Chen,et al.  High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia , 2009, Annals of Hematology.

[25]  T. Papayannopoulou,et al.  Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. , 2009, Experimental hematology.

[26]  P. Mcsweeney,et al.  Plerixafor Can Predictably Mobilize Hematopoietic Stem Cells in Patients With Multiple Myeloma Previously Treated With Lenalidomide , 2009 .

[27]  J. Dipersio,et al.  Effect of Plerixafor (AMD 3100) Plus G-CSF on Tumor Cell Mobilization Among Patients With Lymphoma , 2009 .

[28]  R. De Cristofaro,et al.  The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura , 2009, Haematologica.

[29]  M. Territo,et al.  Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  H. Atkins,et al.  Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma , 2009, Bone Marrow Transplantation.

[31]  H. Goldschmidt,et al.  A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. , 2009, Cytotherapy.

[32]  L. Kanz,et al.  Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma , 2009, Journal of Cancer Research and Clinical Oncology.

[33]  W. Shannon,et al.  Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor , 2008 .

[34]  J. Ritz,et al.  Autologous Peripheral Blood Stem Cell Products from Patients with Hematologic Malignancies Have Increased Frequency of Regulatory T Cells (CD4+FoxP3+ Treg). , 2008 .

[35]  S. Keshavjee,et al.  Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of Reduction of Immunosuppression or Systemic Chemotherapy , 2008 .

[36]  Yi Zheng,et al.  Mobilization of Hematopoitic Stem/Progenitor Cells by a Cdc42 Activity-Specific Inhibitor , 2008 .

[37]  M. Kurokawa,et al.  Pbx-1 Is a Direct Target of Evi-1 in Hematopoietic Stem/Progenitors and Leukemic Cells. , 2008 .

[38]  J. Dipersio,et al.  Rapid Mobilization of Long Term Repopulating Hematopoietic Stem Cells (HSC) with AMD15057, a Small Molecule Inhibitor of VLA4; Synergism with AMD3100 and G-CSF , 2008 .

[39]  Pratibha Singh,et al.  The Combination of AMD3100 Plus GROβ Rapidly Mobilizes Hematopoietic Stem Cells with Enhanced Homing, Adhesion and Survival Properties , 2008 .

[40]  G. Raskob,et al.  Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin , 2008 .

[41]  M. Hoshen,et al.  MicroRNA Is Prognostic Indicator in Patients with Diffuse Large B Cell Lymphoma , 2008 .

[42]  R. Vij,et al.  Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. , 2008, Blood.

[43]  F. Marincola,et al.  Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis , 2008, Journal of Translational Medicine.

[44]  F. Baleux,et al.  CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. , 2008, Blood.

[45]  G. Morgan,et al.  The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients , 2008, Bone Marrow Transplantation.

[46]  R. Barker,et al.  Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. , 2008, Blood.

[47]  Kai-Hsin Chang,et al.  Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. , 2008, Blood.

[48]  H. Hartung,et al.  The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. , 2008, Blood.

[49]  G. Tricot,et al.  AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data , 2008, Bone Marrow Transplantation.

[50]  M. Ruzek,et al.  Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo. , 2008, Blood.

[51]  S. Bridenbaugh,et al.  Clinical stem-cell sources contain CD8+CD3+ T-cell receptor-negative cells that facilitate bone marrow repopulation with hematopoietic stem cells. , 2008, Blood.

[52]  P. L. Bergsagel,et al.  Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma , 2008, Leukemia.

[53]  Mei-Jie Zhang,et al.  CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[54]  N. Geller,et al.  Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100. , 2007 .

[55]  Y. Gazitt,et al.  Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. , 2007, Stem cells and development.

[56]  K. Bradstock,et al.  Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation , 2007, Bone Marrow Transplantation.

[57]  G. Salles,et al.  Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. , 2007, Haematologica.

[58]  Taoyong Chen,et al.  Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. , 2007, Blood.

[59]  S. Fukuda,et al.  The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. , 2007, Blood.

[60]  R. Fonseca,et al.  Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma , 2007, Leukemia.

[61]  D. Nachbaur,et al.  Regulatory T-Cells in the Graft and the Risk of Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation , 2007, Transplantation.

[62]  G. Ehninger,et al.  Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma , 2007, Annals of Hematology.

[63]  J. Dipersio,et al.  Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[64]  Linda Yang,et al.  Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow , 2007, Proceedings of the National Academy of Sciences.

[65]  N. Russell,et al.  Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant‐eligible patients with non‐Hodgkin lymphoma and Hodgkin disease , 2007, British journal of haematology.

[66]  T. Papayannopoulou,et al.  Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. , 2007, Experimental hematology.

[67]  Stefan Fruehauf,et al.  Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation , 2007, European journal of haematology.

[68]  S. Markovic,et al.  AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. , 2007, Clinical lymphoma & myeloma.

[69]  A. Nagler,et al.  Changes in Gene Expression Pattern following Granulocyte Colony-Stimulating Factor Administration to Normal Stem Cell Sibling Donors , 2006, Acta Haematologica.

[70]  R. Wong,et al.  Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. , 2006, Biochemical pharmacology.

[71]  K. Rezvani,et al.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. , 2006, Blood.

[72]  S. Rankin,et al.  Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro , 2006, British journal of haematology.

[73]  H. Goldschmidt,et al.  The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. , 2006, Experimental hematology.

[74]  K. Tarte,et al.  Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor1 , 2006, The Journal of Immunology.

[75]  Ari Elson,et al.  Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells , 2006, Nature Medicine.

[76]  C. Dunbar,et al.  AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. , 2006, Blood.

[77]  Y. Gazitt,et al.  No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. , 2006, Stem cells and development.

[78]  Bryon D Johnson,et al.  Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[79]  H. Mayani,et al.  Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin’s lymphoma and multiple myeloma , 2006, Annals of Hematology.

[80]  A. Lange,et al.  Low CXCR4 membrane expression on CD34+ cells characterizes cells mobilized to blood , 2006, Bone Marrow Transplantation.

[81]  J. Maciejewski,et al.  Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival , 2005, Bone Marrow Transplantation.

[82]  R. Storb,et al.  Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. , 2005, Blood.

[83]  D. Link,et al.  G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. , 2005, Blood.

[84]  R. Hills,et al.  Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Christie M. Orschell,et al.  Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist , 2005, The Journal of experimental medicine.

[86]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[87]  B. Wood,et al.  Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist , 2005, Transfusion.

[88]  H. Einsele,et al.  Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation , 2005, Journal of Cancer Research and Clinical Oncology.

[89]  S. Lonial,et al.  A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[90]  S. Alexander,et al.  Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. , 2004, Blood.

[91]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[92]  P. Kourilsky,et al.  Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1 , 2004, The Journal of Immunology.

[93]  A. Dispenzieri,et al.  The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma , 2004, Leukemia.

[94]  A. Zelenetz,et al.  Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.

[95]  T. Banović,et al.  Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. , 2004, Blood.

[96]  R. Alon,et al.  CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. , 2004, Blood.

[97]  A. Anagnostopoulos,et al.  Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy , 2004, Bone Marrow Transplantation.

[98]  R. Barker,et al.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. , 2004, Blood.

[99]  N. Chao,et al.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. , 2004, Blood.

[100]  S. Ansell,et al.  Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma , 2004, Bone Marrow Transplantation.

[101]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[102]  H. Okano,et al.  Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. , 2004, Immunity.

[103]  S. Rankin,et al.  Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. , 2003, Immunity.

[104]  H. Goldschmidt,et al.  Kinetics of Peripheral Blood Stem Cell Mobilization Following G‐CSF‐Supported Chemotherapy , 2003, Stem cells.

[105]  C. Verfaillie,et al.  Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood , 2003, Bone Marrow Transplantation.

[106]  S. Fruehauf,et al.  It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement , 2003 .

[107]  Sung-Bae Kim,et al.  Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[108]  M. Sugrue,et al.  Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma , 2003, Bone Marrow Transplantation.

[109]  C. Porta,et al.  Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor , 2003, Cancer Immunology, Immunotherapy.

[110]  B. Barlogie,et al.  Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen , 2003, British journal of haematology.

[111]  J. Wingard,et al.  Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation , 2003, Leukemia & lymphoma.

[112]  S. Markovic,et al.  Re-infused Autologous Graft Natural Killer Cells Correlates with Absolute Lymphocyte Count Recovery after Autologous Stem Cell Transplantation , 2003, Leukemia & lymphoma.

[113]  A. Órfão,et al.  Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma. , 2003, Haematologica.

[114]  O. Kollet,et al.  The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2mnull mice , 2002, Leukemia.

[115]  E. De Clercq,et al.  Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 , 2002, FEBS letters.

[116]  F. Prósper,et al.  The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen , 2002, Transfusion.

[117]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[118]  David Klatzmann,et al.  CD4+CD25+ Immunoregulatory T Cells , 2002, The Journal of experimental medicine.

[119]  C. Fathman,et al.  Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.

[120]  E. Montserrat,et al.  Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. , 2002, Blood.

[121]  R. Taichman,et al.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 , 2002, Nature Immunology.

[122]  H. Kampinga,et al.  Peripheral blood stem cells differ from bone marrow stem cells in cell cycle status, repopulating potential, and sensitivity toward hyperthermic purging in mice mobilized with cyclophosphamide and granulocyte colony-stimulating factor. , 2002, Journal of hematotherapy & stem cell research.

[123]  S. Ansell,et al.  Early lymphocyte recovery post‐autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease , 2002, British journal of haematology.

[124]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[125]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[126]  W. Chan,et al.  Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  B. Williams,et al.  Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. , 2002, Experimental hematology.

[128]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[129]  H. Bojar,et al.  Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. , 2002, Blood.

[130]  V. Pavone,et al.  Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.

[131]  E. Waller,et al.  DC2 effect on survival following allogeneic bone marrow transplantation. , 2002, Oncology.

[132]  N. Clément,et al.  Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy: a comparison with steady-state bone marrow and peripheral blood. , 2002, Experimental hematology.

[133]  G. Perea,et al.  Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma , 2001, Annals of Hematology.

[134]  D. Schenkein,et al.  Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. , 2001, Blood.

[135]  H. Rugo,et al.  Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  S. Nilsson,et al.  Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. , 2001, Blood.

[137]  W. Chan,et al.  Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation , 2001, Bone Marrow Transplantation.

[138]  S. Lonial,et al.  Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation , 2001 .

[139]  T. Schwartz,et al.  Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor* , 2001, The Journal of Biological Chemistry.

[140]  J. Adelman,et al.  ATP-dependent Activation of the Intermediate Conductance, Ca2+-activated K+ Channel, hIK1, Is Conferred by a C-terminal Domain* , 2001, The Journal of Biological Chemistry.

[141]  T. Fest,et al.  Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. , 2001, Experimental hematology.

[142]  L. Scott,et al.  Synergistic mobilization of hemopoietic progenitor cells using concurrent β1 and β2 integrin blockade or β2-deficient mice , 2001 .

[143]  Y. Gazitt,et al.  Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. , 2001, Journal of hematotherapy & stem cell research.

[144]  S. Rodenhuis,et al.  In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. , 2001, Blood.

[145]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[146]  A. Spencer,et al.  Tumour Kinetics in Multiple Myeloma Before, During, and After Treatment , 2001, Leukemia & lymphoma.

[147]  Y. Gazitt,et al.  Plasma Levels of SDF‐1 and Expression of SDF‐1 Receptor on CD34+ Cells in Mobilized Peripheral Blood of Non‐Hodgkin's Lymphoma Patients , 2001, Stem cells.

[148]  P. Arveux,et al.  Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. , 2000, European journal of cancer.

[149]  L. Kutteh,et al.  Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  S. Heimfeld,et al.  Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. , 2000, Blood.

[151]  S. Singhal,et al.  Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial , 2000, The Lancet.

[152]  M. Barnett,et al.  Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant , 2000, Bone Marrow Transplantation.

[153]  E. Scarpi,et al.  Is There Any Difference in PBPC Mobilization Between Cyclophosphamide Plus G-CSF and G-CSF Alone in Patients with Non-Hodgkin's Lymphoma? , 2000, Leukemia & lymphoma.

[154]  B. Pollock,et al.  Characterization and Outcome of “Hard to Mobilize” Lymphoma Patients Undergoing Autologous Stem Cell Transplantation , 2000, Leukemia & lymphoma.

[155]  T. Lister,et al.  Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. , 2000, The hematology journal : the official journal of the European Haematology Association.

[156]  A. Zelenetz,et al.  Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  H. Lyerly,et al.  A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. , 1999, Journal of hematotherapy & stem cell research.

[158]  R. Kanteti,et al.  Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease: a clinical and molecular analysis , 1999, Bone Marrow Transplantation.

[159]  W. Franklin,et al.  Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. , 1999, Blood.

[160]  A. Ho,et al.  Peripheral blood progenitor cell (PBPC) counts during steady‐state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony‐stimulating factor supported cytotoxic chemotherapy: an update on 100 patients , 1999, British journal of haematology.

[161]  N. Kadowaki,et al.  Reciprocal control of T helper cell and dendritic cell differentiation. , 1999, Science.

[162]  G. Freeman,et al.  CD48-deficient mice have a pronounced defect in CD4(+) T cell activation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[163]  R. Salazar,et al.  Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose Chemotherapy , 1999 .

[164]  A. Tafuri,et al.  Biological characterization of CD34+ cells mobilized into peripheral blood. , 1998, Bone marrow transplantation.

[165]  H. Goldschmidt,et al.  Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. , 1998, Experimental hematology.

[166]  D. Catovsky,et al.  The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue , 1998, Bone Marrow Transplantation.

[167]  W. Zeller,et al.  Delineation of Cell Cycle State and Correlation to Adhesion Molecule Expression of Human CD34+ Cells from Steady‐State Bone Marrow and Peripheral Blood Mobilized Following G‐CSF‐Supported Chemotherapy , 1998, Stem cells.

[168]  H. Goldschmidt,et al.  First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield , 1998, Bone Marrow Transplantation.

[169]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[170]  A. Tabilio,et al.  CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF , 1998, Bone Marrow Transplantation.

[171]  A. Mayol,et al.  Cd34+ cell dose and CD33- subsets : collection and engraftment kinetics in autologous peripheral blood stem cells transplantation , 1998 .

[172]  C. Perreault,et al.  Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. , 1998, Blood.

[173]  R. Arranz,et al.  Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone , 1997, Bone Marrow Transplantation.

[174]  S. Strober,et al.  Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. , 1997, Blood.

[175]  S. Jacobsen,et al.  Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. , 1997, Journal of immunology.

[176]  R. Haas,et al.  Expression of the Human Immunodeficiency Virus Type-1 Coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ Hematopoietic Progenitor Cells , 1997 .

[177]  J. Gabrilove,et al.  Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial. , 1997, Blood.

[178]  I. Weissman,et al.  Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[179]  M. R. Ricciardi,et al.  Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. , 1997, Blood.

[180]  M. Litzow,et al.  Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation , 1997, Bone Marrow Transplantation.

[181]  A. Tsukamoto,et al.  The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. , 1997, Blood.

[182]  David A. Williams,et al.  Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy , 1996, Nature Medicine.

[183]  M. Cavo,et al.  Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. , 1996, Journal of hematotherapy.

[184]  S. Ikehara,et al.  Characterization of peripheral blood stem cells in mice. , 1996, Blood.

[185]  Hiromitsu Nakauchi,et al.  Long-Term Lymphohematopoietic Reconstitution by a Single CD34-Low/Negative Hematopoietic Stem Cell , 1996, Science.

[186]  A. Lichtenstein,et al.  Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. , 1996, Bone marrow transplantation.

[187]  R. Storb,et al.  Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. , 1996, Bone marrow transplantation.

[188]  H. Goldschmidt,et al.  Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. , 1996, Bone marrow transplantation.

[189]  B. Barlogie,et al.  Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. , 1996, Blood.

[190]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[191]  N. Schmitz,et al.  Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. , 1995, Blood.

[192]  L. Schwartzberg,et al.  An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.

[193]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  M. Andreeff,et al.  Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. , 1995, Blood.

[195]  S. Rodenhuis,et al.  Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  B. Cocks,et al.  A novel receptor involved in T-cell activation , 1995, Nature.

[197]  K. Kaushansky.  Thrombopoietin: the Primary Regulator of Megakaryocyte and Platelet Production , 1995, Thrombosis and Haemostasis.

[198]  H. Goldschmidt,et al.  Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. , 1995, Blood.

[199]  S. Rodenhuis,et al.  Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. , 1995, Blood.

[200]  R. Möhle,et al.  Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. , 1995, Blood.

[201]  H. Goldschmidt,et al.  Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells. , 1995, Blood.

[202]  Y. Ikeda,et al.  Platelet Unresponsiveness to Collagen: Involvement of Glycoprotein Ia-IIa (α2β1 Integrin) Deficiency Associated with a Myeloproliferative Disorder , 1995, Thrombosis and Haemostasis.

[203]  R. Möhle,et al.  Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. , 1994, Bone marrow transplantation.

[204]  A. Keating,et al.  Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. , 1994, Experimental hematology.

[205]  N. Schmitz,et al.  G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.

[206]  H. Goldschmidt,et al.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.

[207]  C. Eaves,et al.  Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. , 1994, Blood.

[208]  W. Zeller,et al.  CD34 selection for purging in multiple myeloma and analysis of CD34+ b cell precursors , 1994, Stem cells.

[209]  N. Davidson,et al.  Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. , 1993, Blood.

[210]  J. Gribben,et al.  Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. , 1993, Blood.

[211]  P. Mauch,et al.  Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. , 1993, Blood.

[212]  D. Littman,et al.  Development and function of T cells in mice with a disrupted CD2 gene. , 1992, The EMBO journal.

[213]  B. Ness,et al.  Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. , 1992, Blood.

[214]  P. Lansdorp,et al.  Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. , 1991, Blood.

[215]  B. Bostrom,et al.  Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. , 1990, Blood.

[216]  D. Weisenburger,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. , 1989, Blood.

[217]  J. Villeval,et al.  Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. , 1988, Blood.

[218]  M. Socinski,et al.  GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN , 1988, The Lancet.

[219]  G. Marit,et al.  Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. , 1986, Experimental hematology.

[220]  B. Dörken,et al.  Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. , 1986, Blood.

[221]  D. Weisenburger,et al.  Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. , 1986, Experimental hematology.

[222]  L. To,et al.  Circulating autologous stem cells collected in very early remission from acute non‐lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy , 1985, British journal of haematology.

[223]  P. Neiman,et al.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.

[224]  R. Weiner,et al.  Increase in Circulating Stem Cells Following Chemotherapy in Man , 1976 .

[225]  W. Cutting,et al.  ORAL REHYDRATION IN RURAL INDIA , 1976, The Lancet.

[226]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.

[227]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[228]  G. Mathé,et al.  Adoptive immunotherapy of acute leukemia: experimental and clinical results. , 1965, Cancer research.

[229]  A. A. Samwick,et al.  INTRAMEDULLARY (STERNAL) TRANSFUSION OF HUMAN BONE MARROW: PRELIMINARY REPORT , 1940 .

[230]  E. E. Osgood,et al.  APLASTIC ANEMIA TREATED WITH DAILY TRANSFUSIONS AND INTRAVENOUS MARROW; CASE REPORT , 1939 .